Want to join the conversation?
Steve Scala of Cowen asks about Sutent long-term outlook, given the competition from immuno-oncology agents. $PFE President Albert Bourla said that the company is confident in its position in the Sutent and Inlyta space. $PFE is studying Inlyta plus other PD-1 inhibitors aggressively to achieve better results than monotherapy in RCC second line.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!